MTCM
CERO

Mint Tower Capital Management’s CERo Therapeutics CERO Stock Holding History

Mint Tower Capital Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71
Closed -$1.55M – 221
2023
Q4 		$1.55M Hold
71
– – 0.35% 66
2023
Q3 		$1.53M Hold
71
– – 0.25% 94
2023
Q2 		$1.54M Hold
71
– – 0.15% 87
2023
Q1 		$1.51M Hold
71
– – 0.16% 89
2022
Q4 		$1.45M Buy
71
+31
+78% +$632K 0.13% 146
2022
Q3 		$807K Buy
+40
New +$806K 0.06% 282

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
PA
Pineridge Advisors St. Charles, Missouri $350M AUM 6.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mint Tower Capital Management's CERO Position: Q1 2024 in Review

Mint Tower Capital Management sold out of CERo Therapeutics (CERO) in Q1 2024, closing a stake of 71 shares — an estimated $1.55M sold.

Mint Tower Capital Management first reported a position in CERO in Q3 2022 and held it in 6 quarters. The position peaked at $1.55M in Q4 2023. 7 funds tracked by Wall St. Rank hold CERO as of Q1 2024.

  • Mint Tower Capital Management reported no remaining CERo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Mint Tower Capital Management sold 71 CERo Therapeutics shares in Q1 2024, an estimated $1.55M.
  • Mint Tower Capital Management first reported a position in CERo Therapeutics in Q3 2022 and held it in 6 quarters.
  • Mint Tower Capital Management's CERo Therapeutics position peaked at $1.55M in Q4 2023.
  • 7 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2024.

Based on Mint Tower Capital Management's 13F filing for Q1 2024, filed 14 May 2024.